Accrual, Publication Bias, and the Coronavirus in 2020

The era of COVID19 reflects the importance, perhaps now more than ever, of transparency in the outcomes of trials small and large. The Oncologist Clinical Trial Results (CTR) section has endeavored to provide a remedy for the persistent problem of underreporting in clinical trials in oncology and th...

Descripción completa

Detalles Bibliográficos
Autor principal: Bates, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356711/
https://www.ncbi.nlm.nih.gov/pubmed/32462787
http://dx.doi.org/10.1634/theoncologist.2020-0455
Descripción
Sumario:The era of COVID19 reflects the importance, perhaps now more than ever, of transparency in the outcomes of trials small and large. The Oncologist Clinical Trial Results (CTR) section has endeavored to provide a remedy for the persistent problem of underreporting in clinical trials in oncology and the subsequent publication bias that this practice necessarily creates. As The Oncologist celebrates its 25th Anniversary, we focus not only on the ethical and moral imperatives behind CTR, but also on the practical goal of informing the practice of treating physicians.

Ejemplares similares